AUS
NZ
UK
CA
USA
IND
Highlights:
Wedbush Initiates Coverage: Wedbush initiated coverage of Rezolute (NasdaqCM: RZLT) on November 5, 2024, with an Outperform rating.
Strong Price Upside Potential: The average one-year price forecast for Rezolute suggests a potential upside of 138.62%, with a range from $7.07 to $15.75 per share.
Increased Institutional Ownership: Institutional ownership in Rezolute has grown, with 78 funds reporting positions, representing a 41.82% increase from the previous quarter.
Wedbush initiated coverage of Rezolute Inc. (NASDAQ:RZLT) with an Outperform recommendation. This analysis follows strong performance indicators for the company, suggesting a favorable outlook.
As of October 22, 2024, the average one-year price estimate for Rezolute is $13.00 per share. The price range for the stock is projected to be between $7.07 and $15.75, with the average estimate implying a potential upside of 138.62% from its most recent closing price of $5.45 per share.
Rezolute is advancing therapies targeting rare, metabolic, and life-threatening conditions. The company’s lead asset, RZ358, is currently in Phase 2b development for the treatment of congenital hyperinsulinism (CHI), a rare pediatric endocrine disorder. In addition to RZ358, the company is also developing RZ402, an orally available plasma kallikrein inhibitor poised to enter clinical trials for diabetic macular edema.
Institutional ownership in Rezolute has increased significantly, with 78 funds or institutions reporting positions as of the last quarter, representing a 41.82% rise in ownership. The total shares held by institutional investors rose by 44.51% to 39,671K shares. Among the key institutional holders, Federated Hermes has raised its position by 9.97% to hold 20.17% of the company, while Federated Kaufmann Fund increased its stake by 15.94%, taking its total ownership to 6.84%.
The growth in institutional interest and the company’s promising clinical pipeline make Rezolute a notable player in the biopharmaceutical sector. The company’s ongoing development efforts, particularly in its rare disease treatments, are expected to play a crucial role in its future success.
Fintel, a comprehensive financial research platform, tracks data on company fundamentals, analyst coverage, institutional holdings, and more, providing valuable insights into potential market movements.
